We’re confident it can help ADVANTAGE attain their goals in the delivery of quality oncology care for their associates,’ said Eduardo Beruff, chief executive officer and president of ITA Companions. Eviti is the first independent, fully-integrated option that simultaneously addresses the quality and cost concerns of cancer patients, insurance and oncologists companies, in virtually any treatment setting. Patients reap the benefits of appropriate treatment for their cancer; while physicians are empowered with systematic access to the latest, most comprehensive, evidence-based treatment standards, along with the advantage of streamlined reimbursement.Total common shares outstanding, net of treasury shares, were 30,255,at December 31 707, 2010. 2011 Financial Guidance AMRI Chief Financial Officer Tag T. Frost provided contract revenue assistance for the first quarter and full calendar year 2011. ‘For the full year 2010 our publication to costs ratio was 1.26. Predicated on this and our current backlog of projects we are optimistic about our revenue growth for 2011. In the first quarter, we expect contract revenue to range from $37 million to $41 million. For the entire calendar year 2011, we expect contract revenue to range from $179 million to $187 million, an increase as high as 15 percent versus 2010.’ Mr. We estimate that our agreement business gross margin will approximate 7 percent to 10 percent, research and development expenditures will decrease by up to 10 percent and selling, general and administrative expenditures increase by 4 percent to 6 percent.’ Complete Year Highlights During 2010, AMRI made several noteworthy announcements like the following: Business Activities The acquisition of Excelsyn Ltd., a well known leader in offering chemical substance development and manufacturing services to the pharmaceutical sector in Europe, located in North Wales, U.K., immediately expanding the business’s products and services, geographic footprint and marketplace share in Europe.